Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

2.

Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.

Bowman BM, Sebolt KA, Hoff BA, Boes JL, Daniels DL, Heist KA, Galbán CJ, Patel RM, Zhang J, Beer DG, Ross BD, Rehemtulla A, Galbán S.

Sci Signal. 2015 Jan 27;8(361):ra9. doi: 10.1126/scisignal.2005607. Erratum in: Sci Signal. 2015 Mar 17;8(368):er3.

3.

Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis.

Lemasson B, Galbán CJ, Boes JL, Li Y, Zhu Y, Heist KA, Johnson TD, Chenevert TL, Galbán S, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Oct 1;6(5):554-61. eCollection 2013.

4.

DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.

Williams TM, Galbán S, Li F, Heist KA, Galbán CJ, Lawrence TS, Holland EC, Thomae TL, Chenevert TL, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Apr;6(2):133-42. Epub 2013 Apr 1.

5.

Metastatic pancreatic cancer is dependent on oncogenic Kras in mice.

Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, Galbán CJ, Galbán S, di Magliano MP.

PLoS One. 2012;7(12):e49707. doi: 10.1371/journal.pone.0049707. Epub 2012 Dec 3.

6.

Multimodal imaging of growth and rapamycin-induced regression of colonic adenomas in apc mutation-dependent mouse.

Miller SJ, Heist KA, Feng Y, Galbán CJ, Rehemtulla A, Ross BD, Fearon ER, Wang TD.

Transl Oncol. 2012 Oct;5(5):313-20. Epub 2012 Oct 1.

7.

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD.

PLoS One. 2012;7(4):e35857. doi: 10.1371/journal.pone.0035857. Epub 2012 Apr 20.

Supplemental Content

Loading ...
Support Center